NCT03044626 - Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Carcinoma，Non-Small-Cell LungMetastatic Lung CancerNonsmall Cell Lung CancerLung Adenocarcinoma MetastaticLarge Cell Lung Carcinoma Metastatic

Interventions

DRUG

Radiotherapy

"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"

DRUG

Nivolumab

Nivolumab 240 mg fixed dose (q2w)

Trial Locations (16)

13125

Evangelische Lungenklinik Berlin, Berlin

13359

DRK Kliniken Berlin Mitte, Berlin

22927

LungenClinic Grosshansdorf, Großhansdorf

51109

Kliniken der Stadt Köln Krankenhaus Merheim, Cologne

60488

Krankenhaus Nordwest, Frankfurt am Main

66421

Universitätsklinikum des Saarlandes, Homburg/Saar

68167

Universitätsklinikum Mannheim, Mannheim

69126

Universitätsklinikum Heidelberg, Heidelberg

73730

Klinikum Esslingen GmbH, Esslingen am Neckar

74245

Klinik Löwenstein, Löwenstein

82131

Asklepios Fachkliniken München-Gauting, München-Gauting

87509

Klinikverbund Kempten-Oberallgäu, Immenstadt im Allgäu

89081

Universitätsklinikum Ulm, Ulm

90419

Klinikum Nürnberg, Nuremberg

09116

Klinikum Chemnitz, Chemnitz

01307

Universitätsklinikum Carl-Gustav-Carus, Dresden